Gilead Sciences (NASDAQ: GILD) generated an average annual return of 15.54% over the past five years, outperforming the broader market by 4.4% on an annualized basis.

The company currently holds a market capitalization of $179.70 billion. Based on a stock price of $144.92 at the time of writing, an initial investment of $1,000 made five years ago would be worth $2,054.32 today.

Performance Overview

The data highlights the impact of compounded returns on long-term capital growth. The total return calculation includes price appreciation over the specified period.

What the Numbers Show

The divergence between the company's annualized return of 15.54% and its market outperformance of 4.4% implies that the benchmark market index returned approximately 11.14% annually over the same period. This spread underscores Gilead's relative strength against broader market movements during this timeframe.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Gilead Sciences (NASDAQ: GILD) announced that the European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab). The approval covers adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy and whose tumors express PD-L1 with a combined positive score of 10 or higher.

This decision follows the recent EC approval of Trodelvy as a monotherapy for patients who are not candidates for PD-1 or PD-L1 inhibitor therapy. Together, these approvals establish Trodelvy as the backbone therapy for patients with first-line metastatic TNBC across PD-L1 status in Europe.

Clinical Data and Regulatory Scope

The approval is based on data from the Phase 3 ASCENT-04 /KEYNOTE-D19 study. The trial demonstrated a highly statistically significant and clinically meaningful progression-free survival for Trodelvy plus Keytruda versus standard of care chemotherapy plus Keytruda. In the study, Trodelvy demonstrated a 35% reduced risk of disease progression or death in patients with PD-L1-positive metastatic TNBC.

Trodelvy plus Keytruda is the first and only antibody-drug conjugate (ADC) plus immunotherapy combination to be approved in first-line metastatic TNBC in the European Union’s 27 member states, as well as Norway, Iceland and Liechtenstein.

What the Numbers Show

The dual approvals position Trodelvy to address the full spectrum of first-line metastatic TNBC. By securing authorization for both monotherapy (for non-PD-1/PD-L1 candidates) and combination therapy (for PD-L1 positive patients), Gilead has established a unified treatment backbone regardless of biomarker status. This strategy leverages the drug’s existing clinical legacy in later lines of therapy and its safety profile in more than 75,000 patients treated globally since 2020.

Disease Context and Safety Profile

Metastatic TNBC accounts for approximately 15% of all breast cancers. It has a higher chance of recurrence and metastases than other breast cancer types. The average time to metastatic recurrence for TNBC is approximately 2.6 years compared with 5 years for other breast cancers. Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of metastatic breast cancer.

Trodelvy carries a boxed warning for neutropenia and diarrhea. In the ASCENT-04 study, serious adverse reactions occurred in 38% of patients, and 7% permanently discontinued Trodelvy due to adverse reactions. Fatal adverse reactions occurred in 3.2% of patients in this study.